NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BiPER Therapeutics

BiPER Therapeutics

Private
StrasbourgHealthcare & Life Scienceshttps://biper-tx.com/

Last Round

SAFE

Dec 2, 2025

Total Funding Raised

$3.35M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

BiPER Therapeutics is a biotechnology company that develops first-in-class small molecule therapeutics targeting BiP to treat cancer and other diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

biotechnologydrug discoverysmall moleculeoncologyprecision medicineBiP inhibitorgastrointestinal cancerpreclinical biotechdrug developmentendoplasmic reticulum stressER stresstherapeutic pipelinedrug candidatebiotech startupAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BiPER Therapeutics Comps

Public and private peers based on sector, stage, and business model.

BiPER Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

BiPER Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SAFEDec 2, 2025
Convertible DebtDec 17, 2024
SeedFeb 14, 2023
View all Funding Rounds

Key People

Founding team and executive leadership

Mehdi Chelbi

Co-founder and Chief Executive Officer

Founding Team

Stéphane MILOT

Chief Financial Officer

Executive Team

BiPER Therapeutics Investors

Notable investors and investment history

BiPER Therapeutics investors
InvestorRounds
MEDIN VCSAFE
WiSeedSeed, Convertible Debt
BpifranceSeed, Convertible Debt, SAFE
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Grew 36% QoQ, from 11 to 15 employees.

  • Apr 23, 2026

    Grew 40% QoQ, from 10 to 14 employees.

View all signals

BiPER Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BiPER Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BiPER Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersStrasbourg
Employee Range15
Year Founded2021
Last FundingDec 2, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.